Form 4: Akoya Biosciences CEO Brian McKelligon Reports Tax-Related Stock Disposal
SEC Form 4 Filing
Brian McKelligon, CEO of Akoya Biosciences, disposed of 7,135 shares of common stock on March 23, 2024, to cover taxes related to a previously granted restricted stock unit award.
Summary
- On March 23, 2024, Brian McKelligon, the President and CEO of Akoya Biosciences, Inc., disposed of 7,135 shares of common stock.
- The transaction was executed to cover taxes on a restricted stock unit award that was previously granted on March 23, 2022.
- The restricted stock unit award vests in four equal annual installments, starting on March 23, 2023.
- Following the transaction, McKelligon directly owns 224,733 shares of Akoya Biosciences common stock.
Sentiment
Score: 5
Explanation: This is a neutral event related to tax obligations on vested stock, with no inherent positive or negative implications for the company's performance.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. This filing indicates a standard tax-related stock disposal, which is common when restricted stock units vest.
Key Dates
| Date | Description |
|---|---|
| 03/23/2022 | Date of original restricted stock unit award grant. |
| 03/23/2023 | First vesting date of the restricted stock unit award. |
| 03/23/2024 | Date of stock disposal for tax withholding. |
| 03/25/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.